Back

Role of clopidogrel loading dose in patients undergoing transcatheter aortic valve implantation: results from the BRAVO-3 randomized trial

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Current data on TAVI outcomes Non coronary cardiac interventions ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Vincent Johan Nijenhuis

St Antonius Hospital, Nieuwegein (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Transcatheter aortic valve implantation: efficacy, safety and mortality at 30-days to 1-year from a nationwide eight year registry
Doctor P. Canas da Silva (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Medtronic CoreValve vs Edwards Sapien: a comparative analysis of efficacy, safety and mortality from an eight year nationwide registry
Doctor P. Canas da Silva (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Impact of residual coronary artery disease on patients undergoing TAVI: a multicenter study
Doctor S. Taha (Assiut, EG)
Abstract Slides
Presentation thumbnail
Effect of body mass index on mortality after transcatheter aortic valve implantation: J-shaped curve.
Ms R. GONZALEZ FERREIRO (Vigo, ES)
Abstract
Presentation thumbnail
Acute kidney injury following transcatheter aortic valve implantation: does it affect long-term outcomes?
Doctor A. Bacelar (Sao Paulo, BR)
Abstract Slides

Access the full session

Session thumbnail
Current data on TAVI outcomes

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources